Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA

Watchlist Manager
Sun Pharmaceutical Industries Ltd Logo
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Watchlist
Price: 1 795.3 INR 0.86% Market Closed
Market Cap: 4.3T INR
Have any thoughts about
Sun Pharmaceutical Industries Ltd?
Write Note

Sun Pharmaceutical Industries Ltd
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Sun Pharmaceutical Industries Ltd
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Total Equity
â‚ą691.1B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
12%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Total Equity
â‚ą282.5B
CAGR 3-Years
17%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Total Equity
â‚ą283.6B
CAGR 3-Years
13%
CAGR 5-Years
13%
CAGR 10-Years
10%
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Total Equity
â‚ą198.3B
CAGR 3-Years
15%
CAGR 5-Years
14%
CAGR 10-Years
19%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Total Equity
â‚ą75B
CAGR 3-Years
6%
CAGR 5-Years
8%
CAGR 10-Years
12%
M
Mankind Pharma Ltd
NSE:MANKIND
Total Equity
â‚ą93.6B
CAGR 3-Years
26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Sun Pharmaceutical Industries Ltd
Glance View

Market Cap
4.3T INR
Industry
Pharmaceuticals

Sun Pharmaceutical Industries Ltd. is a leading global pharmaceutical company based in India, renowned for its commitment to producing high-quality generic and specialty medicines. Founded in 1983, Sun Pharma has evolved into one of the largest pharmaceutical companies in India and the fifth largest globally in the generic market. With a robust portfolio that encompasses various therapeutic areas, including cardiology, psychiatry, neurology, and oncology, the company has built a solid reputation for innovation and reliability. A strong emphasis on research and development drives Sun Pharma’s growth, helping it to continuously expand its product offerings and tap into new markets, as evidenced by its strategic acquisitions and partnerships over the years. For investors, Sun Pharmaceutical presents a compelling opportunity, underpinned by its solid financial performance and a forward-looking strategic vision. The company's extensive presence in over 150 countries combined with a diverse portfolio fuels its competitive edge in the global pharmaceutical landscape. With a solid track record of profitability and a commitment to enhancing shareholder value, Sun Pharma is well-positioned to capture growth in emerging markets and capitalize on advancements in biologics and complex generics. Moreover, the company’s focus on sustainability and ethical practices resonates in an increasingly socially conscious investment environment, making it an appealing prospect for investors looking to diversify their portfolios while supporting a responsible industry leader.

SUNPHARMA Intrinsic Value
1 046.73 INR
Overvaluation 42%
Intrinsic Value
Price

See Also

What is Sun Pharmaceutical Industries Ltd's Total Equity?
Total Equity
691.1B INR

Based on the financial report for Sep 30, 2024, Sun Pharmaceutical Industries Ltd's Total Equity amounts to 691.1B INR.

What is Sun Pharmaceutical Industries Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
12%

Over the last year, the Total Equity growth was 16%. The average annual Total Equity growth rates for Sun Pharmaceutical Industries Ltd have been 12% over the past three years , 10% over the past five years , and 12% over the past ten years .

Back to Top